UK - Lyceum Capital to acquire AIM-listed Synexus in £18m deal
Lyceum Capital Partners has announced a recommended cash offer of 78p per share to shareholders for Synexus Clinical Research Plc. AIM-listed Synexus is the largest European-headquartered business recruiting patients for late phase clinical trials on behalf of pharmaceutical and biotechnology companies. The offer values the company at just over ТЃ18m.
More on Buyouts
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Main Capital's Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
TPG takes majority control of A-Gas, doubles down on impact investing
KKR partially exits its 2017 investment in the specialty gas and chemical distributor, retaining a minority stake
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund
The Silver Economy Fund makes its second investment as it highlights trend of GPs doubling down on narrow strategies
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds